BeiGene to present updated data on Brukinsa

BeiGene announced that it will present data on its Bruton’s tyrosine kinase inhibitor, or BTKi, Brukinsa at the 17th International Conference on Malignant Lymphoma, or ICML, which is taking place from June 13-17 in Lugano, Switzerland. In an updated analysis from the Phase 2 ROSEWOOD trial shared as an oral presentation at ICML, Brukinsa in combination with obinutuzumab demonstrated clinically meaningful activity and was generally well-tolerated in patients with heavily pretreated relapsed or refractory, or R/R, follicular lymphoma, or FL. Brukinsa in combination with obinutuzumab showed an overall response rate of 69.0% versus 45.8% in the obinutuzumab arm and median follow-up of 20.2 months. The complete response rate for Brukinsa in combination with obinutuzumab was 39.3% compared to 19.4% for obinutuzumab alone. Non-hematologic treatment-emergent adverse events of any grade that occurred more frequently in the combination group were petechiae and herpes zoster infection; in contrast, pyrexia and infusion-related reaction occurred more frequently in patients receiving obinutuzumab alone. These results will be presented on June 16, 2023, 3:30 – 5:00 pm CEST. Demonstrating a commitment to developing rigorous evidence for potential new treatments for rare hematologic malignancies, BeiGene will detail the trial design of its Phase 3 MAHOGANY study of Brukinsa plus obinutuzumab versus lenalidomide plus rituximab in R/R FL or marginal zone lymphoma in an oral presentation during the Ongoing Trials Session.